Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 227

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?

Gentilella, Raffaella, Pechtner, Valeria, Corcos, Antonella, Consoli, Agostino · 2019 · Diabetes/Metabolism Research and Reviews

Abstract

Summary: Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes mellitus. Agents in this class are derived from either exendin‐4 (a compound present in Gila monster venom) or modifications of human GLP‐1 active fragment. Differences among these drugs in duration of action (ie, short‐acting vs long‐acting), effects on glycaemic control and weight loss, immunogenicity, tolerability profiles, and administration routes offer physicians several options when selecting the most appropriate agent for individual patients. Patient preference is also an important consideration. The aim of this review is to discuss the differences between and similarities of GLP‐1 RAs currently approved for clinical use, focusing particularly on the properties characterising the single short‐acting and long‐acting GLP‐1 RAs rather than on their individual efficacy and safety profiles. The primary pharmacodynamic difference between short‐acting (ie, exenatide twice daily and lixisenatide) and long‐acting (ie, albiglutide, dulaglutide, exenatide once weekly, liraglutide, and semaglutide) GLP‐1 RAs is that short‐acting agents primarily delay gastric emptying (lowering postprandial glucose) and long‐acting agents affect both fasting glucose (via enhanced glucose‐dependent insulin secretion and reduced glucagon secretion in the fasting state) and postprandial glucose (via enhanced postprandial insulin secretion and inhibition of glucagon secretion). Other advantages of long‐acting GLP‐1 RAs include smaller fluctuations in plasma drug concentrations, improved gastrointestinal tolerability profiles, and simpler, more convenient administration schedules (once daily for liraglutide and once weekly for albiglutide, dulaglutide, the long‐acting exenatide formulation, and semaglutide), which might improve treatment adherence and persistence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/dmrr.3070

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 227

Metadata

Authors
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A.
Venue
Diabetes/Metabolism Research and Reviews
Publisher
Wiley
Published
2018-10-04
Volume
35
Issue
1
Pages
e3070-e3070
ISSN
  • 1520-7552 (ISSN-L)
  • 1520-7560
OpenAlex
W2889521172
Cited by
227
References
50
FWCI
17.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same? https://app.cochat.ai/papers/10.1002/dmrr.3070
The paper
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019). Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same? Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.